Michael Truett Tate - 07 Aug 2025 Form 4/A - Amendment Insider Report for Astera Labs, Inc. (ALAB)

Signature
/s/ Philip Mazzara, Attorney-in-Fact
Issuer symbol
ALAB
Transactions as of
07 Aug 2025
Net transactions value
-$17,138,485
Form type
4/A - Amendment
Filing time
20 Aug 2025, 17:02:36 UTC
Date Of Original Report
11 Aug 2025
Previous filing
29 Jul 2025
Next filing
14 Aug 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Tate Michael Truett Chief Financial Officer C/O ASTERA LABS, INC., 2345 NORTH FIRST STREET, SAN JOSE /s/ Philip Mazzara, Attorney-in-Fact 20 Aug 2025 0001399546

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALAB Common Stock Sale $7,324,352 -43,184 -7% $169.61 575,812 07 Aug 2025 By Tate Trust F1, F2
transaction ALAB Common Stock Sale $1,286,064 -7,550 -1.3% $170.34 568,262 07 Aug 2025 By Tate Trust F2, F3
transaction ALAB Common Stock Sale $2,596,345 -15,141 -2.7% $171.48 553,121 07 Aug 2025 By Tate Trust F2, F4
transaction ALAB Common Stock Sale $5,931,724 -34,125 -6.2% $173.82 518,996 07 Aug 2025 By Tate Trust F2, F5
transaction ALAB Common Stock Gift $0 -7,500 -1.4% $0.000000 511,496 07 Aug 2025 By Tate Trust F2, F6
transaction ALAB Common Stock Gift $0 -10,000 -2% $0.000000 501,496 08 Aug 2025 By Tate Trust F2, F7
holding ALAB Common Stock 278,373 07 Aug 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $169.0500 to $169.9900, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $170.0500 to $170.8600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $171.0800 to $171.8500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $173.5950 to $174.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 Represents a bona fide gift of shares to a non-affiliated entity.
F7 Represents a bona fide gift of shares to a non-affiliated person.

Remarks:

This Form 4/A (this "Amendment") amends and restates in its entirety the original Form 4 filed with the U.S. Securities and Exchange Commission on August 11, 2025 (the "Original Form") to remove the transaction relating to the acquisition of Astera Labs, Inc. common stock ("Common Stock") by GlobalStar Donor Advised Fund ("DAF"), of which the Reporting Person was inadvertently reported due to administrative error as being a trustee. In fact, the Reporting Person has no pecuniary interest in GlobalStar DAF; as such, the 7,500 shares were gifted to and acquired by a non-affiliated entity, as reported in this Amendment.